Over the past two decades there have been few advances in the drug therapy of schizophrenia which reflects, in part, the limitations of the animal tests used to screen for neuroleptic agents. A series of valuable animal tests were initially described by Janssen and colleagues (1965a, b, 1966) and these led to the development of many of the most valuable neuroleptic agents in common use today. However, all the potent neuroleptics of the butyrophenone, phenothiazine and other groups have similar activity spectra and all agents have the potential to induce the undesirable extrapyramidal effects of dystonias, Parkinsonlike symptoms and, more speculatively, tardive dyskinesias.
If advances were to be made in the treatment of schizophreniform symptoms it became evident that refinements and innovations in the field of behavioural screens were essential. This problem was emphasized by analysis of the laboratory spectra of metoclopramide which caused typical neuroleptic-type changes in animal behaviour (Janssen et al. 1966 , Costall & Naylor 1973 whilst reportedly lacking antipsychotic activity (Borenstein & Bles 1965) ; and by thioridazine and the more recently introduced 'antipsychotics', sulpiride and clozapine, which were shown to be virtually inactive in the most widely used tests for neuroleptic agents, the catalepsy and antistereotypy tests (Janssen et al. 1967 , Laville & Margarit 1968 , Sayers & Kleinlogel 1974 and 2). In our laboratories we have investigated possible modifications to existing tests and have developed new behavioural models for the detection of more specific neuroleptic agents. This paper reports on these new tests and is not. an attempt to review all possible tests for antipsychotic activity.
The above observations appear not only to question the validity of the animal models used for the detection of antipsychotic potential but also our present understanding of the pathology of schizophrenia, since both catalepsy and stereotypy have been shown to depend on the integrity of mesolimbic as well as extrapyramidal function (Costall & Naylor 1973 , 1974 . For thioridazine, sulpiride and clozapine, the minimal effect on the extrapyramidal dopamine mechanisms would relate to clinical reports of low extrapyramidal disturbance with these agents Dr R J Naylor (Goldman 1961 , De Maio 1969 , Haase et al. 1974 but a low efficacy on mesolimbic dopamine mechanisms would appear contrary to present concepts of antipsychotic drug action.
However, it could also be considered that the failure of these atypical agents in the behavioural tests may reflect their weak ability to block dopamine receptor(s) (Bartholini et al. 1972) between 8 a.m. and 8 p.m. in a sound-proofed, diffusely illuminated room maintainedat 21 ± J'C. Each value is the mean maximum response of6-8 rats. Standard errors are all less than 10 % ofthe mean therefore, that the blockade may be easily overcome by increased transmitter release and/or by concomitant anticholinergic action (Miller & Hiley 1974 , Muller & Seeman 1974 , Snyder et al. 1974 which would tend to block the proposed balance between cholinergic and dopaminergic mechanisms (see Muller & Seeman 1974) .
If these hypotheses were correct, then it may be expected that a reduction in dopamine function (as caused by a-methylparatyrosine) or an enhanced cholinergic activity (as induced by the centrally acting cholinergic agent RS86) should facilitate the development of the neuroleptic behavioural effects. This was shown to be so (see also Costall & Naylor 1975a) . Pretreatment of rats with 250 mg/kg i.p. of a-methylparatyrosine was shown significantly to potentiate the cataleptic actions of haloperidol, fluphenazine, pimozide, metoclopramide, thioridazine and sulpiride, but failed to modify the action ofclozapine. Threshold cataleptic doses of all agents, except metoclopramide, markedly synergized in the production of catalepsy with threshold doses of RS86 (Figs 3 and 4). Similar observations were made for cholinergic synergism against the antistereotypic effects of the typical and atypical neuroleptic agents (Figs 5 and 6).
These studies show clearly that the neuroleptic properties of thioridazine, sulpiride and clozapine can be detected by the widely-used catalepsy and antistereotypy tests, provided that the doses used are related to the therapeutic range when comparisons are made to the typical neuroleptics. Also, manipulation of cerebral dopaminergic and/or cholinergic mechanisms in favour of dopamine blockade is shown to reveal the neuroleptic potential of antipsychotic drugs which initially appear to lack these typical behavioural effects. Thus, it is clear that the properties of thioridazine, clozapine and sulpiride do not invalidate the use of the catalepsy and antistereotypy tests for the detection of potential antipsychotic activity. It is the particular way in which the tests are applied which determines the outcome.
It is a basic working hypothesis that neuroleptic agents act via cerebral dopamine mechanisms (Hornykiewicz 1977) although it is appreciated that the functional state of other neurotransmitter substances may be modified by neuroleptic action. The relatively high concentrations of dopamine found in the olfactory tubercle, nucleus accumbens, nucleus septalis lateralis, lateral and central nucleus of the amygdala, median eminence and ventral tegmental area, and the modest amounts in the substantia nigra and cingulate, entorhinal andfrontal cortex ( test. Effects ofmodifying the so called cholinergic-dopaminergic balance on the cataleptic actions ofatypical 'neuroleptic' agents. a 'neuroleptic' alone; E 'neuroleptic' administered 6 h after pretreatment with 250 mg/kg i.p. of cx-methylparatyrosine; M thresholddose ofRS86 5 mg/kg i.p.; * thresholddose of RS86 combined with a thresholddose of neuroleptic'. RS86 and the neuroleptic agents were administered at the same time, excepting thioridazine which was given 4 h before the dose of RS86. The intensity ofthe catalepsy was assessed according to the system indicated in Fig 1  legend . Each value is the mean maximum response of6-10 rats. Standard errors are all less than 18 % ofthe means combining a threshold dose ofneuroleptic with a thresholddose ofthe cholinergic agent RS86, 5 mg/kg i.p. M. The combination is indicated by the following hatching S. Stereotyped behaviour was induced by 10 mg/kg i.p. ofd-amphetamine and 2 mg/kg s.c. ofapomorphine. The intensity of stereotypy was initially assessedaccording to the simple scoring system 0 = no stereotypedbehaviour; 1 = periodic sniffing and/or repetitive headand limb movements; 2= continuous sniffing and/or repetitive head and limb movement; 3=periodic gnawing, biting or licking; 4= continuous gnawing, biting or licking. The doses ofd-amphetamine andapomorphine selectedeach gave consistent score 4 stereotypy.
Haloperidol andfluphenazine were given 30 min before the stereotypic agents, pimozide 4 h before. In the combination studies, RS86 was given 4 h after a threshold antistereotypic dose ofpimozide or at the same time as the other neuroleptic agents. Changes in stereotypedbehaviour are expressed as the % inhibition by the neuroleptic agents ofthe maximum score stereotypy induced by d-amphetamine and apomorphine. Each value is the mean ofdeterminations from at least 8 rats. Standard errors are all less than 15 % ofthe means conditions initially indicated two distinct ascending telencephalic dopamine projections, the nigrostriatal and the mesolimbic systems (Ungerstedt 1971) . More recently, however, studies on the innervation to the cortex have indicated a further dopamine-containing 'mesocortical' system and possible cross connections between the different systems (Fig 7) . It is on these systems that the neuroleptic agents are considered to exert their major effects to reduce the symptoms of schizophrenia (mesolimbic and mesocortical systems) and induce extrapyramidal disturbance (nigrostriatal system) but, as already indicated, the commonly used behavioural tests fail to differentiate neuroleptic action on these different dopamine systems. Models which allowed such differentiations were considered the essential bases for the development of neuroleptic agents having more specific activity spectra.
Behavioural indices of neuroleptic action on mesolimbic and/or extrapyramidal dopamine mechanisms were developed by the use of the intracerebral injection technique. The actions of typical and atypical neuroleptic agents were Changes in stereotyped behaoviour are expressed as the % inhibition by the 'neuroleptic' agents ofthe maximum score stereotypy induced by d-amphetamine and apomorphine. Each value is the mean of determinationsfrom at keast 8 rats. Standard errors are all less than 16% ofthe means determined by the hyperactivity induced by dopamine injected intracerebrally into the extrapyramidal caudate-putamen or mesolimbic nucleus accumbens (Costall & Naylor 1976a (1971), Berger et al. (1976) and Simon et al. (1976) putamen, againi, in a dose-dependent manner but, generally, somewhat larger doses were required than in the accumbens model (Fig 9) . Of great interest, the latter model was found to be sensitive to the actions of thioridazine, clozapine and sulpiride. These agents, virtually inactive in the classical tests for neuroleptic action, reduced or abolished the hyperactivity induced by dopamine from the nucleus accumbens in a dose-dependent manner and using pharmacologically acceptable doses. Of equal interest was the failure of metoclopramide, even at supramaximal cataleptic doses, to antagonize the accumbens hyperactivity ( Fig  10) . The value of this model is therefore stressed. It will detect an apparent dopamine blocking action of both typical and atypical antipsychotic agents at relatively low doses and appears unique in eliminating the non-antipsychotic agent metoclopramide. All the atypical agents, clozapine, sulpiride, thioridazine and metoclopramide, were shown to antagonise the hyperactivity induced by dopamine from the caudate-putamen ( Fig 11) . Again, larger doses of the antipsychotic agents were required as compared with the accumbens hyperactivity. However, a strict comparison of the doses of neuroleptic agents required to inhibit the hyperactivity from the nucleus accumbens and caudate-putamen could not be consistently correlated with their antipsychotic potency or their ability to induce Parkinson-like effects in man.
It is considered possible that the 'caudate induce Parkinson-like side-effects, but to induce side effects which are extrapyramidal in origin. For example, metoclopramide was shown to be effective in the 'caudate model' but does not induce or exacerbate Parkinsonian symptoms, although this drug will induce dystonic reactions (see also Costall & Naylor 1976 ). The above model, based on the effects of dopamine administered directly into the cerebral tissues of the mesolimbic and extrapyramidal systems in the rat, has been extensively applied in our laboratories to 'screen' the action of a large number of putative neuroleptic agents, but the methodology involving stereotaxic surgery is laborious. The value of data obtained from the use of this model is emphasized, but it was considered that a more simple screen might be developed to give some possible indication of the relative effect of a drug on the extrapyramidal and mesolimbic systems.
In the rat, apomorphine induces a stereotyped behaviour but a dose-related hyperactivity is conspicuously absent (Costall & Naylor 1976b ). This contrasts with observations in the mouse which can respond to apomorphine with increased locomotion, usually characterized by constant movement about the holding cage. If the cage is lined with wire mesh then animals exhibit a constant climbing behaviour which can be measured. Initial reports in the literature indicated that this climbing behaviour could be inhibited by typical neuroleptics and by sulpiride and clozapine (Peuch et al. 1976 , Protais et al. 1976 , Baldessarini et al. 1977 . It was therefore decided to analyse this behaviour in greater depth, not only to establish its value for detecting agents having antipsychotic action, but also to serve as a possible basis to differentiate drugs which have marked or little effect on the extrapyramidal system.
Two measures of climbing behaviour were determined. Firstly was the percentage of time an animal spent climbing during the 30 min period following the first climb. This was termed the climbing index. The second measure was the maximum time, in min, spent by an animal in a single climb, throughout the duration of the apomorphine effect. Throughout extensive studies, these two measures were found to be parallel. However, if a drug caused muscular hypotonia (for example, clozapine) the maximum time was reduced but the climbing index was not.
Climbing behaviour involves fine motor coordination and, therefore, the need to check for such non-specific interactions is essential. The design of the experiments must therefore allow for assessment of sedation, catalepsy or a change in the apomorphine response from increased locomotion to stereotyped behaviour which, by definition, is a restricted behaviour and could interfere with active climbing behaviour. Therefore, although this model would lend itself to automation (Farrant et al. 1977 ), this would not eliminate the need for 'manual' observation.
As a test for antipsychotic activity, mouse climbing has the advantage of ease and simplicity of execution but, like many other tests, it initially appears to fail by including the non-antipsychotic agent metoclopramide. This agent, like typical and atypical neuroleptics, caused a dosedependent reduction in the intensity of the apomorphine-induced climbing behaviour (Table  1) . However, subsequent studies apparently allowed the differentiation of agents having marked effects on the extrapyramidal system. Apomorphine appears to have been tacitly accepted simply as a directly acting dopamine agonist and, indeed, it does possess many properties to be expected of such an agent. However, there is evidence in the literature to suggest an involvement of serotonin with the actions of apomorphine (Grabowska et al. 1973) .
Therefore, a most interesting aspect of the mouse climbing model was the clear involvement of serotonergic mechanisms. Whilst the serotonin agonist, quipazine, reduced or abolished the apomorphine induced climbing, the serotonin Table 1 kntagonism of the climbing behaviour induced by apomorphine n the mouse by typical and atypical neuroleptic agents Climbing behaviour was induced by the s.c. administration of 1.0 mg/kg of apomorphine to mice. Potential antagonists were idministered by the i.p. route before apomorphine (pretreatment times indicated in parentheses). The climbing index represents :he percentage oftime spent climbing during the 30 min period ifter the first climb. The second measure of climbing behaviour represents the maximum time spent in a single climb throughout the duration ofthe apomorphine effect. Animals with doses lesignated 0 received saline 30 min before apomorphine antagonists, methysergide and cyproheptadine, 6nhanced the behaviour. Just as it has been assumed that apomorphine is a dopamine agonist per se, it is also assumed that antipsychotic agents act simply by dopamine blockade. This may not be the rule, since the antagonistic effects of clozpine, thioridazine and iulpiride on climbing behaviour were reduced by methysergide (Table 2) . However, a clear difference was apparent between these agents and haloperidol (and other typical neuroleptic drugs) ind metoclopramide whose effects were not reduced by methysergide or cyproheptadine ' Table 3 ). It is interesting to note that the latter agents have clear potential to modify cerebral lopamine function in man so as to induce Iystonias or Parkinson-like effects whilst clozapine, thioridazine and sulpiride are reported as possessing low efficacy to induce these effects. Possibly, the use of the mouse climbing model with serotonergic antagonists such as methysergide and/or cyproheptadine may aid the search for Climbing behaviour was induced in all animals (including the controls) by the s.c. administration of 1.0 mg/kg ofapomorphine to mice. Thioridazine, clozapine and sulpiride were injected i.p. 60 min before apomorphine, methysergide 30 min before. Doses ofthese agents were carefully selected from full dose-response curves. The climbing index represents the percentage oftime spent climbing during the 30 min period after the first climb. The second measure ofclimbing behaviour represents the maximum time spent in a single climb throughout the duration ofthe apomorphine effect Table 3 Attempted reversal by serotonergic antagonism of the reduction in mouse climbing behaviour caused by typical behaviour neuroleptic agents Climbing behaviour was induced in all animals (including the controls) by the s.-. administration of 1.0 mg/kg ofapomorphine to mice. Methysergide and metoclopramide were injected i.p. 30 min before apomorphine, haloperidol 20 min before. The doses ofhaloperidol, metoclopramide and methysergide were carefully selected from full dose-response curves. The climbing index represents the percentage oftime spent climbing during the 30 min period after the first climb. The second measure of climbing behaviour represents the maximum time spent in a single climb throughout the duration ofthe apomorphine effect antipsychotic agents lacking the undesirable side effects noted above (Costall, Naylor & Nohria, unpublished data).
Although it is appreciated that the action of neuroleptic agents is probably under the modulatory influence of several neurotransmitter mechanisms, the induction of stereotyped behaviour and catalepsy in animals or the development of peri-oral dyskinesias or Parkinson-like hypokinesia in man have all been interpreted in terms of a modification of dopaminergic activity (see reviews by Fog 1972 , Korczyn 1972 . Almost without exception it has been implicit in these interpretations that there is a single type of dopaminergic mechanism, stimulation producing the stereotypy/peri-oral dyskinesias whereas blockade will result in catalepsy/Parkinson-like effects. However, recent extensive studies in these and other laboratories have emphasized the need to consider the existence of at least two different populations of dopamine receptor within one brain region (Cools et al. 1975 , Costall et al. 1975b .
In this paper we report on new behavioural tests for antipsychotic agents. Emphasis obviously tends towards the primary detection of the antipsychotic properties of neuroleptic agents. However, as previously outlined, all antipsychotic agents in common clinical use have a potential to induce undesirable side effects. Tests for differentiating between antipsychotic and extrapyramidal side effects have been described, but it was considered important, in view of the seriousness of tardive dyskinesias, to develop models for the detection of antidyskinetic agents.
In order to explain the theoretical bases of the models developed, it was necessary to introduce the new concept of different dopamine receptors. These were termed DA-1 and DA-2 (see also Costall & Naylor 1975b) . It is postulated that stimulation of the DA-1 system increases locomotor activity and that the inhibition of the DA-1 hyperactivity mechanisms may result in the neuroleptic akinesia and, with increasing dosage, a full pseudo-Parkinson syndrome may develop as the result of additional effects, direct or indirect, on other neurotransmitter mechanisms.
At much higher doses than those causing hypoor akinesia, neuroleptic agents will, paradoxically, block those tardive dyskinesias which they cause. It is postulated that this effect is due to a blockade of DA-2 mechanisms which, in comparison to the DA-1 mechanisms, are relatively resistant to neuroleptic blockade. Since very large doses of neuroleptic agents are required to inhibit the DA-2 dyskinetic mechanism, such anti-dyskinetic therapy is invariably associated with a poverty of movement. Clearly, it would be advantageous to develop neuroleptic agents with a selectivity of action on the DA-1 and DA-2 mechanisms. A selective DA-1 antagonist may, theoretically, be of particular value in reducing excessive psychomotor agitation or mania, whereas a selective DA-2 antagonist may have a specific anti-dyskinetic potential.
Our studies on dyskinesias induced in the guinea-pig have indicated three potential DA-2 antagonists, pimozide, oxiperomide and tiapride. However, a complete specificity for the DA-2 mechanisms cannot be claimed for these agents. Pimozide and oxiperomide can undoubtedly affect DA-1 mechanisms and reduce locomotor activity, but the dosage differential for DA-1 and DA-2 antagonism is narrow for these agents and markedly contrasts with that of the classical neuroleptics whose affinity appears to be preferentially for DA-1.
Of the dyskinesia models which have been developed, two have proven particularly valuable. Dopamine injected bilaterally into the striatum of nialamide-pretreated guinea-pigs causes the development of abnormal involuntary movements which are characterized by peri-oral movements, gnawing, biting, protrusion of the tongue and facial grimacing. Less frequently, acute twisting of the head and neck occurs. These dyskinesias, which have been shown to be highly specific for dopamine and dopamine-like drugs (Costall et al. 1975 ) are accompanied by hyperactivity. These dyskinesias are resistant to blockade by large doses of typical neuroleptic agents such as haloperidol and fluphenazine but are completely inhibited by pimozide and by comparatively low doses of oxiperomide (Table  4, Costall & Naylor 1975b) . Table 4 Neuroleptic modification of the dyskinetic phenomena induced by intrastriatal dopamine in the guinea-pig The second model utilizes the putative dopamine agonist 2-(N,N-dipropyl)amino-5,6dihydroxytetralin. This agent, when administered directly into the striatum or peripherally to guinea-pigs, causes the development of peri-oral dyskinesias which, although resembling stereotyped biting, can be differentiated by the relative sensitivity to blockade by the neuroleptic agents. Oxiperomide was shown to be particularly effective in this model (Table 5, Costall et aL 1977) . The value of these models has been verified by the confirmation of an anti-dyskinetic potential for oxiperomide, pimozide and tiapride in preliminary clinical studies. It remains to be seen whether or not dyskinesias will fail to develop after long term treatment with these agents.
The behavioural screening of potential psychoactive drugs ideally requires tests that are simple to apply and accurate in their assessment. Whilst the use of the classical test procedures has indicated numerous agents of potential antipsychotic activity, it is difficult to see how such agents can exert a fundamentally different action, detected as they are by precisely the same experimental profile. However, it is realized that occasionally and virtually by chance, these tests will detect an agent such as pimozide which does possess a different clinical action. Nevertheless, a more rational experimental approach to the detection of novel antipsychotic agents is clearly required and it is suggested that some of the tests described in this manuscript may provide a different emphasis and approach and usefully augment current test procedures.
DISCUSSION
Dr E Szabadi (Manchester) asked Dr Iversen about cellular localization of the dopamine sensitive adenylate cyclase system. Was it localized in neurones, in glial cells, or in both? Dr Iversen (Chairman) said that one possibility for multiple dopamine receptors was that one type might be classical post-synaptic receptors on the surface of neurones or their dendrites and another type might be pre-synaptic receptors involving the release of other transmitters. Unfortunately, the situation was not clear. In the substantia nigra there was evidence that the adenylate cyclase mechanism was entirely presynaptic on afferent terminals to the nigra. It disappeared after lesions of striatal inputs to the nigra. However, within the striatum itself, kainic acid lesions which were alleged to destroy neurones (and therefore presumably postsynaptic receptors) eliminated the adenylate cyclase. It was therefore not possible to generalize, but the notion of two types of receptors was attractive.
Dr R J Naylor asked whether anyone present had experience of compounds such as pimozide inducing dystonia in man.
Dr M Weller (London) had two patients who had been on a combination of pimozide and propranolol. On propranolol alone they had no dystonic reactions, but when pimozide was added in a conventional dosage, both developed extra-pyramidal side effects, severe in one case. In this instance it was particularly localized to the shoulder muscles and the neck, a pattern not dissimilar to that seen with trifluperazine.
The problem often began with ocular difficulties before it extended to the neck and back muscles.
Dr R L Palmer (Leicester) had also treated a young girl receiving pimozide, 8 mg/day who developed oculogyral crises. The drug was stopped and they did not return. The effect seemed to be drug related, because she was not receiving any other medication at the time.
Dr R J Naylor said that it was most important when trying to detect anti-schizophrenic compounds with animal models also to have a clear picture of the activity of these compounds in the clinic. It was frequently difficult to get these data, but they could do little to further the animal models without this clinical information.
Dr T J Crow (London) returned to the question of pre-and post-synaptic dopamine receptors. He asked if any distinction could be made amongst post-synaptic receptors themselves.
Dr R J Naylor said that at the present time it was impossible reliably to distinguish between preand post-synaptic receptorsin any animal model.
New dopamine agonists (so described because their effects were usually very specifically blocked and only blocked by very small doses of neuroleptic agents) produced quite different types of behavioural response. This was particularly true with some of the propyl derivatives which would give a virtually pure dyskinetic effect, a characteristic chewing or gnawing reaction in rodents. One then looked for selective antagonists for this response, which were obviously crucial, if one were to suggest the presence of different dopamine mechanisms. This evidence was more difficult to obtain, but it now seemed that compounds like oxiperomide and its analogues might abolish or reduce the dyskinesias without necessarily abolishing other effects. This was the distinction at the behavioural level, although it was far from satisfactory. Dr L L Iversen (Chairman) believed that the increasing weight of biochemical evidence from in vitro models made it progressively more difficult to rationalize the pharmacology of CNS dopamine receptors on the basis of only one type, but the idea of two types of receptor was still preliminary and had to be viewed with caution.
